Pharmaceutical

STAT+: Patent thickets and terminal disclaimers: How ph...

A new study examines tools that pharma companies use to keep drug prices high an...

Obesity drugs’ next tests, and rising threats: 3 chroni...

It isn't just obesity — chronic liver disease is also an increasing problem in t...

STAT+: Medical marijuana companies are using pharma’s s...

Medical marijuana companies sell medicine, just like pharma companies. But a STA...

STAT’s most memorable photos of 2023

As STAT looks back at 2023 in photographs, the faces of so many stand out.

Opinion: Why haven’t health care cost increases exceede...

Why haven’t health care cost increases exceeded inflation in recent years? There...

STAT+: Drugs are still mostly tested in white men. Will...

Congress gave the FDA more power to get companies to racially diversify clinical...

After ‘SNL’ skit on sickle cell CRISPR therapy, advocat...

“Those two caricatures that they put on national TV is how people view us,” an a...

STAT+: SEC charges former CEO of pain relief device com...

The Securities and Exchange Commission charged Laura Perryman, former CEO of med...

Morning Rounds: Americans put faith in nurses as overal...

Understand how science, health policy, and medicine shape the world everyday. Si...

Inhaled vaccines could stop Covid infections, monkey st...

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: Pharmalittle: Curevac loses key patent in battle...

A German court invalidated a patent at the center of a CureVac lawsuit against B...

STAT+: In another blow, Argenx antibody therapy fails i...

Argenx said Wednesday that its closely watched therapy failed to outperform plac...

STAT+: 3 trends to watch in biotech in 2024

After two years of steady decline in biotech, industry optimists might be onto s...

Opinion: The U.S. must raise federal alcohol taxes to a...

The U.S. must raise federal alcohol taxes to address the alarming rise in alcoho...

MABS-139 by Manhattan Biosolutions for Solid Tumor: Lik...

MABS-139 is under clinical development by Manhattan Biosolutions and currently i...

FLU-SV-mRNA by Curevac for Influenza A Virus, H1N1 Subt...

FLU-SV-mRNA is under clinical development by Curevac and currently in Phase I fo...